Poster
28

Plasma LOXL2 target engagement by GB2064, a high affinity, small-molecule LOXL2 inhibitor, in a phase 1 healthy subject study.

Authors

J Roper1; A Santani2; G Bains2; R Slack1
1 Galecto, Inc., UK;  2 PharmAkea, Inc., UK

Abstract

GB2064 is a high affinity, selective, pseudo-irreversible, small-molecule inhibitor of LOXL2, a secreted glycoprotein that crosslinks extracellular matrix (ECM) collagens & elastin contributing to the stiffness & loss of function of fibrotic organs, that is currently being developed for myelofibrosis. In this study we describe the target engagement (TE) of plasma LOXL2 by GB2064 in a phase 1 healthy subject study using an exploratory assay with ferrite beads chemically coupled to a LOXL2 inhibitor to capture only free/unbound LOXL2. A single-centre, randomised, placebo-controlled study was completed to assess safety, tolerability, & PK/PD of GB2064 in 78 healthy subjects. Single doses (150 to 2500 mg) & multiple doses of GB2064 (150 to 2000 mg QD or 1000 mg BID) for 7 days were found to be safe & well tolerated with no appreciable accumulation in plasma & steady state attained within 1-2 days. When dosed orally GB2064 bound circulating plasma LOXL2 & inhibited the capture of LOXL2 by inhibitor-coupled beads. At 2 h post-dosing, binding to LOXL2, defined as TE, increased in a dose-related fashion with near maximal target engagement observed at doses at or above 750 mg. The in vivo IC50 (905 nM) for LOXL2 binding/TE was shown to be very comparable to that determined in vitro in human blood (715 nM). TE was comparable between identical dosing groups in SAD & MAD & within dosing groups on Day 1 & 7. The consistency of these data illustrates the reproducibility of this exploratory assay & validation for future use in phase 2 clinical studies.

Hosted By

ELRIG
The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Find us on Facebook Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Login
Eventflo Home
copyright ELRIG, eventflo.co.uk, Labhoo Ltd 2003-2021